Ovarian Cancer

Monoclonal Antibody Therapy Presented To European Researchers

Published in Women's Health Weekly, November 29th, 2001

AltaRex Corp.'s (ALXFF) OvaRex monoclonal antibody (MAb), which is in late stage development for the treatment of advanced ovarian cancer, was discussed at a special session on gynecologic cancer therapy at the 11th Annual European Cancer Conference (ECCO) held in Lisbon, Portugal.

The presentation was the first opportunity for AltaRex to present to the collective European oncology community its findings on the relevance of circulating levels of the tumor associated antigen CA125 both as an indicator of impending progression of ovarian cancer and as a target for OvaRex MAb.

The selection of OvaRex MAb for the special session at ECCO 11 recognizes an...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2001-11-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry